Publisher
Springer International Publishing
Reference34 articles.
1. Ramos-Casals, M., et al.: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin. Exp. Rheumatol. 28, 468–476 (2010)
2. Effinger, A., O’Driscoll, C.M., McAllister, M., Fotaki, N.: Impact of gastrointestinal disease states on oral drug absorption–implications for formulation design–a PEARRL review. J. Pharm. Pharmacol. 71, 674–698 (2019)
3. Golder, S., Norman, G., Loke, Y.: Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br. J. Clin. Pharmacol. 80, 878–888 (2015)
4. Sarker, A., et al.: Utilizing social media data for pharmacovigilance: a review. J. Biomed. Inform. 54, 202–212 (2015)
5. Magge, A., et al.: DeepADEMiner: a deep learning pharmacovigilance pipeline for extraction and normalization of adverse drug effect mentions on twitter. medRxiv (2020)